Phase II trials of intratumoral ONYX-015, an E1B 55-kDa gene-deleted adenovirus, alone and in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

被引：0

作者：

Nemunaitis, J

Khuri, F

Ganly, I

Tannock, I

Kuhn, J

McCartey, T

Heise, C

Posner, M

Kaye, S

Romel, L

Landers, S

Kirn, D

机构：

[1] PRN Res Inc, Dallas, TX USA

[2] Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA

[3] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland

[4] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] ONYX Pharmaceut, Richmond, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

O78

引用

页码：S26 / S26

页数：1